Diagnosis and management of cryptococcal disease in resource-limited settings

被引：6
作者：
Vanselow M. [1 ]
Brandt M.E. [1 ]
Park B.J. [1 ]
机构：
[1] Mycotic Diseases Branch, Centers for Disease Control and Prevention, MS C-09, Atlanta, GA 30333
来源：
Current Fungal Infection Reports | 2012年 / 6卷 / 1期
关键词：
Amphotericin; Cryptococcal antigen; Cryptococcal meningitis; Cryptococcosis; Cryptococcus; Diagnosis; Fluconazole; HIV/AIDS; Lateral flow assay; Latex agglutination; Management; Resource-limited settings;
D O I：
10.1007/s12281-011-0082-6
中图分类号：
学科分类号：
摘要：
Cryptococcal meningitis is one of the most important fungal infections in the developing world, where deaths related to this disease are numerous. In resource-limited settings, mortality is high in large part because of difficulties in the diagnosis and management of this infection. This paper outlines many of the realities in many resource-limited settings, and describes priorities for public health action and research. © 2012 Springer Science+Business Media, LLC.
引用
收藏
页码：35 / 40
页数：5
相关论文
共 39 条
[1]  
Ellis D.H., Pfeiffer T.J., Ecology, life cycle, and infectious propagule of Cryptococcus neoformans, Lancet, 336, 8720, pp. 923-925, (1990)
[2]  
Mitchell T.G., Perfect J.R., Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans, Clin Microbiol Rev., 8, 4, pp. 515-548, (1995)
[3]  
Park B.J., Wannemuehler K.A., Et al., Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS, AIDS., 23, 4, pp. 525-530, (2009)
[4]  
Kaplan J.E., Hanson D., Et al., Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy, Clin Infect Dis., 30, SUPPL. 1, (2000)
[5]  
Van Elden L.J.R., Walenkamp A.M.E., Lipovsky M.M., Reiss P., Meis J.F.G.M., De Marie S., Dankert J., Hoepelman A.I.M., Declining number of patients with cryptococcosis in the Netherlands in the era of highly active antiretroviral therapy, AIDS, 14, 17, pp. 2787-2788, (2000)
[6]  
Chen S.C.A., Cryptococcosis in Australasia and the treatment of cryptococcal and other fungal infections with liposomal amphotericin B, Journal of Antimicrobial Chemotherapy, 49, SUPL. S1, pp. 57-61, (2002)
[7]  
Mirza S.A., Phelan M., Rimland D., Graviss E., Hamill R., Brandt M.E., Gardner T., Sattah M., De Leon G.P., Baughman W., Hajjeh R.A., The changing epidemiology of cryptococcosis: An update from population-based active surveillance in 2 large metropolitan areas, 1992-2000, Clinical Infectious Diseases, 36, 6, pp. 789-794, (2003)
[8]  
Dromer F., Mathoulin-Pelissier S., Fontanet A., Ronin O., Dupont B., Lortholary O., Epidemiology of HIV-associated cryptococcosis in France (1985-2001): Comparison of the pre- and post-HAART eras, AIDS, 18, 3, pp. 555-562, (2004)
[9]  
Qkongo M., Morgan D., Mayanja B., Ross A., Whitworth J., Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda, International Journal of Epidemiology, 27, 4, pp. 698-702, (1998)
[10]  
Bogaerts J., Rouvroy D., Taelman H., Kagame A., Aziz M.A., Swinne D., Verhaegen J., AIDS-Associated Cryptococcal meningitis in Rwanda (1983-1992): Epidemiologic and diagnostic features, Journal of Infection, 39, 1, pp. 32-37, (1999)
1234